Trials / Completed
CompletedNCT03489772
Study of ITI-214 in Healthy Volunteers to Determine CNS Engagement
A Randomized, Placebo-Controlled, Double-Blind Study of Escalating Single Doses of ITI-214 in Healthy Volunteers to Determine Central Nervous System Engagement, Safety and Tolerability
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 26 (actual)
- Sponsor
- Intra-Cellular Therapies, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
This is a single site, randomized, double-blind, placebo-controlled, within-subjects study design in healthy volunteers. Escalating single doses of ITI-214 will be evaluated using functional magnetic resonance imaging (fMRI) to determine central nervous system engagement. Safety and tolerability also will be assessed.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ITI-214 | Oral |
| DRUG | Placebo | Oral |
Timeline
- Start date
- 2018-07-10
- Primary completion
- 2019-08-05
- Completion
- 2019-08-05
- First posted
- 2018-04-05
- Last updated
- 2019-11-06
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03489772. Inclusion in this directory is not an endorsement.